Immunotherapy for hormone receptor‒positive HER2-negative breast cancer

被引：0
|
作者：
Fatima Cardoso [1 ]
Kim M. Hirshfield [2 ]
Kimberly A. Kraynyak [2 ]
Konstantinos Tryfonidis [2 ]
Aditya Bardia [3 ]
机构：
[1] Champalimaud Clinical Center/Champalimaud Foundation,Breast Unit
[2] Inc.,Merck & Co.
[3] Jonsson Comprehensive Cancer Center,Department of Medicine, Division of Hematology/Oncology, University of California Los Angeles
来源：
npj Breast Cancer | / 10卷 / 1期
关键词：
D O I：
10.1038/s41523-024-00704-9
中图分类号：
学科分类号：
摘要：
Additional therapies are needed to improve outcomes in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.
引用
收藏
相关论文
共 50 条
  • [31] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [32] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
  • [33] Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer
    Joo, Eun Hye
    Kim, Sangmin
    Park, Donghyun
    Lee, Taeseob
    Park, Woong-Yang
    Han, Kyung Yeon
    Lee, Jeong Eon
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (11)
  • [34] Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer
    Sestak, Ivana
    Filipits, Martin
    Buus, Richard
    Rudas, Margaretha
    Balic, Marija
    Knauer, Michael
    Kronenwett, Ralf
    Fitzal, Florian
    Cuzick, Jack
    Gnant, Michael
    Greil, Richard
    Dowsett, Mitch
    Dubsky, Peter
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4682 - 4687
  • [35] Appraising Adjuvant Endocrine Therapy in Hormone Receptor Positive HER2-Negative Breast Cancer-A Literature Review
    de Mello Morais Mata, Danilo Giffoni
    Carmona, Carlos Amir
    Eisen, Andrea
    Trudeau, Maureen
    CURRENT ONCOLOGY, 2022, 29 (07) : 4956 - 4969
  • [36] Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
    Falato, Claudette
    Schettini, Francesco
    Pascual, Tomas
    Braso-Maristany, Fara
    Prat, Aleix
    CANCER TREATMENT REVIEWS, 2023, 112
  • [37] Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Joseph Gligorov
    Jean-Pierre Lotz
    Breast Cancer Research and Treatment, 2008, 112 : 53 - 66
  • [38] A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer
    Harbeck, Nadia
    Burstein, Harold J.
    Hurvitz, Sara A.
    Johnston, Stephen
    Vidal, Gregory A.
    CANCER, 2022, 128 : 2209 - 2223
  • [39] Association of Endocrine Therapy with Survival for Patients with Small, Hormone Receptor-Positive, HER2-Negative, Breast Cancer
    Ma, S. J.
    Oladeru, O. T.
    Sood, A. J.
    Mikucki, M.
    Farrugia, M. K.
    Singh, A. K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E74 - E74
  • [40] Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
    Kovac, Anja
    Kuhar, Cvetka Grasic
    Ovcaricek, Tanja
    Matos, Erika
    Mencinger, Marina
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345